With an established number of licensed medical indications, Botulinum Toxin type A (BoNT-A) is also globally acknowledged to effectively refine many of the senescent changes which occur in the ageing face. BoNT-A is widely considered to be an effective first line therapy to eradicate dynamic lines, as well as an adjunctive treatment for a number of aesthetic rejuvenation strategies in softening more established rhytides. The exceptional popularity of the products for aesthetic use and the new potential applications currently under investigation remain unabated. Such demand reinforces the importance of continuous educational updates for the medical practitioner to provide valuable information on the evolving aesthetic and medical modalities, ensuring an optimal understanding of the uses of the product, and safe treatment outcomes for the patient.
Key words: Botulinum Toxin type A, emerging indications, delivery devices, pharmacology, dermatology, pain
